DIPEPTIDYL PEPTIDASE-4 INHIBITORS WERE ASSOCIATED WITH THE REDUCED LONG-TERM RISK OF ADVERSE CARDIOVASCULAR EVENTS IN JAPANESE DIABETIC PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Although dipeptidyl-peptidase-4 inhibitors (DPP4i) are one of the most popular antidiabetic agents worldwide, major randomized trials of DPP4i have failed to demonstrate the benefit of DPP4i to reduce the risk of adverse cardiovascular events in secondary prevention. This retrospective analysis